CLDN18.2 Expression and Regional Variability in Early Gastric Cancer

Background Claudin 18.2 (CLDN18.2) is an established therapeutic biomarker in advanced gastric cancer, but its expression in early gastric cancer remains incompletely characterized. This study aimed to describe the prevalence, clinicopathological associations, and regional staining patterns of CLDN18.2 in early gastric cancer. Methods We retrospectively analyzed 54 early gastric cancers resected by endoscopic submucosal dissection. CLDN18.2 immunohistochemistry was evaluated using computer-assisted semiquantitative image analysis with pathologist review. Positivity was defined as moderate-to-strong (≥2+) membranous staining in ≥75% of viable tumor cells. Regional status was assessed in three tumor-center regions (Regions A-C) and one deepest/advancing tumor area (Region D). Results CLDN18.2 positivity was identified in 38 of 54 tumors (70%) and was not significantly associated with histological differentiation (two-sided Fisher–Freeman–Halton exact P = .229), Ki-67 expression, p53 staining pattern, or MLH1 status. Thirty-five tumors (65%) showed consistent status across the four regions, whereas 19 (35%) showed regional discordance. A tumor-center-positive/Region D-negative pattern was observed in 8 of 54 tumors (15%). Positivity differed across the four paired regions (Cochran Q = 26.90, P < .001), and Region D had a lower positivity rate than each tumor-center region in pairwise analyses (all Bonferroni-adjusted P ≤ .006). Conclusions CLDN18.2 expression was relatively common in this early gastric cancer cohort, and regional staining variability was observed in a subset of tumors. These findings extend the pathological characterization of CLDN18.2 in early gastric cancer by describing its prevalence and regional expression patterns.

Authors

Institutions

Publication Details

Journal
International Journal of Surgical Pathology
Published
2026-11-18
DOI
https://doi.org/10.1177/10668969261506921
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CLDN18.2 Expression and Regional Variability in Early Gastric Cancer

Zheng Jin, Zecan Shi, Haojie He, 谢乐斯 et al.
6 links
International Journal of Surgical Pathology
Gastric Cancer Management and Outcomes
article

CLDN18.2 Expression and Regional Variability in Early Gastric Cancer

Zheng Jin, Zecan Shi, Haojie He, 谢乐斯, Hangbin Jin, Yangyang Zheng, Xiaofeng Zhang, Tong Huan
article en

Abstract

Background Claudin 18.2 (CLDN18.2) is an established therapeutic biomarker in advanced gastric cancer, but its expression in early gastric cancer remains incompletely characterized. This study aimed to describe the prevalence, clinicopathological associations, and regional staining patterns of CLDN18.2 in early gastric cancer. Methods We retrospectively analyzed 54 early gastric cancers resected by endoscopic submucosal dissection. CLDN18.2 immunohistochemistry was evaluated using computer-assisted semiquantitative image analysis with pathologist review. Positivity was defined as moderate-to-strong (≥2+) membranous staining in ≥75% of viable tumor cells. Regional status was assessed in three tumor-center regions (Regions A-C) and one deepest/advancing tumor area (Region D). Results CLDN18.2 positivity was identified in 38 of 54 tumors (70%) and was not significantly associated with histological differentiation (two-sided Fisher–Freeman–Halton exact P = .229), Ki-67 expression, p53 staining pattern, or MLH1 status. Thirty-five tumors (65%) showed consistent status across the four regions, whereas 19 (35%) showed regional discordance. A tumor-center-positive/Region D-negative pattern was observed in 8 of 54 tumors (15%). Positivity differed across the four paired regions (Cochran Q = 26.90, P < .001), and Region D had a lower positivity rate than each tumor-center region in pairwise analyses (all Bonferroni-adjusted P ≤ .006). Conclusions CLDN18.2 expression was relatively common in this early gastric cancer cohort, and regional staining variability was observed in a subset of tumors. These findings extend the pathological characterization of CLDN18.2 in early gastric cancer by describing its prevalence and regional expression patterns.

International Journal of Surgical Pathology
Zhejiang Chinese Medical University (CN), Westlake University (CN), Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
Good health and well-being
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon